You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明系股價逆市三連升 獲大行唱好藥明生物屢破頂 藥明巨諾漲逾8%
藥明系股價三連升,藥明生物(02269.HK)上周五高管調高今年營運指引,將全年銷售及盈利增長預測由原先50%提高至65%後,大摩、高盛及瑞信分別升價8.6%至152元、逾20%至157.9元及21.5%至158元,以反映調高公司未來幾年盈測。該股三連升,承上周破頂強勢,今天逆市進一步升至142.6元屢創紀錄高,現造138.2元,續升4.6%,成交額32.26億元。

同系藥明康德(02359.HK)重越10天及20天線,最高見169.9元,現造168.3元,續升1.8%。此外,由藥明康德及美國醫藥研發平台Juno共同投資的內地臨床及臨床前階段細胞治療公司去年11月才上市的藥明巨諾(02126.HK)重越50天線(29.74元),最高見31.15元,現造30.6元,續升8.1%,成交額1.85億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account